PT-141 (Bremelanotide) Employer and ICHRA Coverage: How to Pay Less in 2026

What Is PT-141 and Why Is Coverage So Complicated?

Bremelanotide, sold as Vyleesi and widely called PT-141 in compounded form, is a melanocortin receptor agonist that acts centrally to increase sexual desire rather than increasing genital blood flow the way PDE-5 inhibitors work in men. The FDA approved Vyleesi in August 2019 specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), the most common female sexual dysfunction diagnosis in the United States.

Coverage is complicated for two reasons. First, payers routinely classify sexual-health drugs as "lifestyle" or "elective" and carve them out of medical formularies, even when an FDA-approved indication clearly exists. Second, compounded PT-141, which is chemically the same peptide at a fraction of the brand price, sits in a regulatory gray zone that makes formulary coverage essentially impossible, though HSA and FSA reimbursement may still apply with a valid prescription.

Why Women Bear a Disproportionate Coverage Burden

Men's sexual-dysfunction drugs, including sildenafil and tadalafil, have achieved broad formulary placement and generic pricing after two decades on the market. Vyleesi has not. A 2022 analysis in the Journal of Women's Health found that insurance coverage for FDA-approved female sexual-dysfunction treatments lagged substantially behind coverage for equivalent male indications, a disparity that persists on most employer and marketplace plans in 2026.

HSDD affects an estimated one in ten premenopausal women at any given time, and prevalence rises during perimenopause and in the postpartum period, two phases of hormonal flux that can suppress desire independently of relationship or psychological factors. The coverage gap is not a niche problem.

How Traditional Employer Health Plans Handle Bremelanotide

Most large-group employer plans administered by major PBMs (Express Scripts, CVS Caremark, OptumRx) do not include Vyleesi on their standard national formulary tiers. The drug may appear as a non-covered exclusion or require prior authorization with a specialty tier co-pay that can reach $400-$600 per fill even when technically covered.

Checking Your Summary Plan Description

Your plan's Summary Plan Description (SPD) is the controlling document. Look for:

• A sexual-health exclusion clause. If present, no appeal will succeed without a medical-necessity override, which requires a clinician's letter and sometimes a peer-to-peer review call.
• The specialty formulary tier list. Vyleesi occasionally appears on Tier 4 or Tier 5 specialty tiers.
• A compounding exclusion. Nearly all commercial plans explicitly exclude compounded medications unless the commercially available version is unavailable or medically contraindicated.

Filing a Medical-Necessity Appeal

Your WomanRx clinician can write a letter documenting your HSDD diagnosis using validated tools such as the Female Sexual Distress Scale-Revised (FSDS-R) and the Female Sexual Function Index (FSFI). A score of 24 or below on the FSFI correlates with sexual dysfunction and supports medical-necessity documentation. Plans that receive a structured appeal overturn denials at a meaningful rate, though published data on Vyleesi-specific appeals are limited.

ICHRA: The Coverage Path Most Women Have Not Tried

An Individual Coverage Health Reimbursement Arrangement (ICHRA) is an employer-funded account that reimburses employees for individual health insurance premiums and, depending on plan design, qualified medical expenses including prescription drugs. Since 2020, employers of any size can offer ICHRAs, and the Treasury and DOL finalized rules permitting broad ICHRA use.

Here is a practical decision framework for using ICHRA dollars toward bremelanotide in 2026:

Step 1, Confirm Your ICHRA Type

ICHRAs come in two designs relevant here:

• Premium-only ICHRA: Reimburses individual plan premiums but not drug costs directly.
• Premium-plus ICHRA: Reimburses premiums AND qualified medical expenses under IRC Section 213(d), which includes FDA-approved prescription drugs.

Ask your HR administrator which type you have. If yours is premium-plus, bremelanotide with a valid prescription qualifies as a reimbursable expense under 26 U.S.C. § 213(d) so long as your employer's plan document does not carve out sexual-health drugs.

Step 2, Submit a Reimbursement Request Correctly

You need three documents:

1. A dated, signed prescription from a licensed clinician (a WomanRx NP or MD prescription qualifies in states where telehealth prescribing is authorized).
2. An itemized pharmacy receipt showing the drug name, quantity, cost, and dispensing date.
3. Your insurer's or ICHRA administrator's reimbursement claim form.

Compounded PT-141 is trickier. The IRS has not published explicit guidance excluding compounded drugs from Section 213(d), but some ICHRA administrators apply a "commercially available equivalent" rule and deny claims for compounded versions when brand Vyleesi exists. Get your administrator's written policy before filling a compounded order if you intend to seek ICHRA reimbursement.

Step 3, Appeal a Denial With IRS Guidance

If your ICHRA administrator denies a claim, cite IRS Publication 502, which lists "prescription drugs" broadly as deductible medical expenses. An HSDD diagnosis in your medical record strengthens the argument that this is treatment for a recognized medical condition, not a lifestyle choice.

HSA and FSA: The Most Reliable Low-Barrier Option

Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) are governed by IRC Section 213(d). Any prescription drug for a diagnosed medical condition qualifies. This means that if your clinician documents an HSDD diagnosis and writes a prescription, you can pay for Vyleesi or compounded PT-141 with pre-tax HSA or FSA dollars.

The tax savings are real. A woman in the 22% federal bracket paying $600 per fill out-of-pocket saves approximately $132 per fill by routing the purchase through an HSA. Over four fills in a year, that is more than $500 in net savings before any state income tax benefit.

HSA vs. FSA for This Specific Drug

| Feature | HSA | FSA | |---|---|---| | Requires high-deductible health plan | Yes | No | | Funds roll over year to year | Yes | Typically no (use-it-or-lose-it) | | Works for Vyleesi brand | Yes, with Rx | Yes, with Rx | | Works for compounded PT-141 | Yes, with Rx (administrator discretion) | Yes, with Rx (administrator discretion) | | Requires diagnosis documentation | Recommended | Recommended |

Carry a copy of your prescription and HSDD diagnosis code (ICD-10 F52.0) in case your HSA debit card is flagged for a pharmacy purchase that an automated system treats as a non-medical item.

Manufacturer Savings Programs and Patient Assistance

Palatin Technologies and its commercial partners have offered savings programs since Vyleesi's 2019 launch, but availability and terms change frequently. As of mid-2025, check the following directly before assuming a program is active:

• Vyleesi.com savings card: Historically reduced out-of-pocket cost for commercially insured patients to as little as $99 per fill for eligible women. Card programs commonly exclude government-insured patients (Medicare, Medicaid).
• Patient Assistance Program (PAP): For uninsured or underinsured patients meeting income thresholds, PAPs may provide medication at no cost. Contact Palatin's medical affairs line or ask your WomanRx clinician to submit a PAP request on your behalf.

These programs are not guaranteed to be active in 2026. Programs change when manufacturers restructure contracts or exit co-pay assistance arrangements. Verify current availability at the time of your prescription.

Compounded PT-141: Lower Cost, Different Regulatory Status

Compounded bremelanotide is widely available through 503A compounding pharmacies with a clinician's prescription. Typical pricing runs $100-$300 for a multi-dose vial, compared to the brand Vyleesi price near $1,000 per autoinjector. The cost differential is significant enough that many women use compounded PT-141 even when brand Vyleesi would be covered, simply because the out-of-pocket co-pay on brand can exceed compounded cash price.

What the FDA Says About Compounded PT-141

Compounded bremelanotide is not FDA-approved. The FDA has not placed bremelanotide on its 503B outsourcing facility drug shortage list, which means large-scale compounding of it by 503B facilities occupies a regulatory gray zone. Compounding by 503A pharmacies (patient-specific prescriptions) has continued, but you should understand:

• Quality, sterility, and potency are not independently verified by the FDA.
• Formulations vary across pharmacies. Dose accuracy matters for both efficacy and safety.
• Insurance, ICHRA premium-only accounts, and FSAs administered by certain third parties may deny reimbursement.

Ask your WomanRx clinician which 503A pharmacies they have vetted for sterility testing and potency verification. This is a meaningful clinical question, not a minor logistical detail.

Pregnancy, Lactation, and Contraception: Required Reading Before You Fill

Bremelanotide is contraindicated in pregnancy. This is a hard stop.

In animal reproductive toxicology studies submitted to the FDA, bremelanotide caused fetal harm at doses used in humans. The Vyleesi prescribing information carries a warning to discontinue the drug if pregnancy is detected and advises women of reproductive potential to use effective contraception during treatment.

What This Means Across Life Stages

Reproductive years (trying to conceive): Do not use bremelanotide while actively attempting pregnancy. If you are working with a fertility specialist or using assisted reproductive technology, discuss timing with both your reproductive endocrinologist and your WomanRx clinician. HSDD is common in women undergoing fertility treatment, where the medicalization of sex can suppress desire, but bremelanotide must be stopped before any cycle in which conception is possible. ASRM guidelines on sexual dysfunction in fertility patients recommend addressing desire disorders with non-teratogenic options first when conception is the goal.

Postpartum and lactation: No adequate data exist on bremelanotide transfer into human breast milk. Animal data are insufficient to rule out risk. Given the drug's mechanism of action (central melanocortin receptor agonism), the theoretical concern for neurological effects in a nursing infant exists. The prescribing information recommends avoiding use during breastfeeding. Postpartum HSDD is extremely common and often resolves as prolactin normalizes and hormones stabilize after weaning. Non-pharmacologic approaches and, where appropriate, hormonal support should be considered first in nursing mothers. This gap in lactation data is a genuine evidence gap, not an oversight in this article.

Perimenopause: Bremelanotide carries an FDA indication specifically for premenopausal women. Perimenopausal women, whose hormonal status fluctuates and may not consistently meet the "premenopausal" definition, occupy an unclear regulatory position. Prescribing in perimenopause is off-label. Desire disorders in perimenopause are often multifactorial, driven by falling estrogen, fluctuating testosterone, sleep disruption, and mood changes. The Menopause Society (NAMS) 2022 position statement on sexual health notes that HSDD treatment should address hormonal contributors before or alongside central-acting agents.

Postmenopause: Off-label use only. The phase 3 trials that led to FDA approval (RECONNECT trials) enrolled premenopausal women. Shifrin et al., published in Obstetrics and Gynecology, reported that 25% of premenopausal women on bremelanotide achieved a meaningful increase in satisfying sexual events vs. 17% on placebo, but postmenopausal data are extrapolated, not direct. If you are postmenopausal and considering bremelanotide, this evidence gap must be part of your shared decision-making conversation.

Contraception Requirement

If you are not trying to conceive and are of reproductive potential, use a reliable contraceptive method during bremelanotide treatment. The prescribing information does not specify a single method, but clinicians typically recommend any highly effective method: IUD, implant, combined hormonal contraception, or sterilization. Note that bremelanotide may transiently reduce systemic drug exposure of some oral medications due to nausea-related decreased absorption; take oral contraceptive pills at a time separated from your bremelanotide dose (typically given 45 minutes before anticipated sexual activity).

Who This Drug May Be Right For, and Who Should Look Elsewhere

Likely Candidates

• Premenopausal women with a documented HSDD diagnosis (low desire causing personal distress, present for at least 6 months, not explained by relationship conflict, medication side effects, or another medical condition as the sole cause)
• Women who have tried non-pharmacologic approaches (sex therapy, addressing relationship factors, sleep, stress management) without adequate improvement
• Women for whom flibanserin (Addyi, a daily oral medication also FDA-approved for HSDD) was ineffective or not tolerated. Flibanserin requires alcohol abstinence, which is a barrier for some women.
• Women who prefer on-demand dosing (bremelanotide is used as needed, not daily)

Not the Right Fit

• Pregnant women or those actively trying to conceive
• Breastfeeding mothers (insufficient safety data)
• Women with uncontrolled hypertension: bremelanotide transiently raises blood pressure by approximately 2-4 mmHg and heart rate, and the prescribing label contraindicates use in women with known cardiovascular disease
• Women whose low desire is primarily driven by a correctable hormonal imbalance (e.g., low estrogen causing dyspareunia that secondarily reduces desire, or hypothyroidism, or uncontrolled PCOS-related androgen imbalance) where treating the underlying condition should come first
• Women on high-dose naltrexone therapy (melanocortin and opioid receptor pathways interact; discuss with your clinician)

Step-by-Step Cost Reduction Checklist for 2026

Use this sequence to minimize what you pay out of pocket:

1. Check your SPD for sexual-health formulary exclusions before requesting a prior authorization.
2. Ask HR whether you have an ICHRA and whether it covers qualified medical expenses under Section 213(d).
3. Confirm HSA or FSA balance and verify your ICHRA administrator's policy on compounded drugs if you prefer compounded PT-141.
4. Request your WomanRx clinician write a medical-necessity letter with your FSFI/FSDS-R scores and ICD-10 code F52.0 for a prior-authorization appeal if your plan technically covers specialty drugs.
5. Check Vyleesi.com for the current savings card. Terms change; verify at the time of prescribing.
6. Ask about the PAP if your household income qualifies.
7. Compare brand vs. Compounded cost with your specific HSA/FSA and ICHRA rules in mind before choosing a pharmacy.
8. Set a calendar reminder for FSA deadlines. FSA funds typically expire December 31 or March 15 of the following year depending on your employer's plan design.

The Evidence Gap: What We Don't Know Yet

Women have been under-studied in sexual-health pharmaceutical research for decades. The RECONNECT trials that supported Vyleesi's approval enrolled approximately 1,200 premenopausal women across two phase 3 studies, which is a reasonable sample for FDA approval but leaves meaningful subgroup gaps. We do not have high-quality published data on:

• Long-term use beyond 52 weeks
• Efficacy in women with surgically induced menopause using bremelanotide off-label
• Interaction with combined hormonal contraceptives beyond the absorption timing concern
• Outcomes specifically in women with HSDD concurrent with PCOS, where androgen excess and hormonal dysregulation may modify response

When your WomanRx clinician discusses bremelanotide with you, they are drawing on regulatory trial data, post-marketing case reports, and clinical experience. Extrapolation is part of the picture, and knowing that is part of making an informed decision.